Results 171 to 180 of about 34,135 (204)

Overexpression of the ERG oncogene in prostate cancer identifies candidates for PARP inhibitor-based radiosensitization. [PDF]

J Clin Invest
Köcher S, Elsesy ME, Moustafa A, Mohammadi W, Perugachi Heinsohn A, Nagaraj Y, Oh-Hohenhorst SJ, Hahn J, Siebels B, Mair T, Burdak-Rothkamm S, Tennstedt P, Simon R, Lange T, Tilki D, Frenzel T, Maurer T, Petersen C, Schlüter H, Bokemeyer C, von Amsberg G, Rothkamm K, Mansour WY.   +22 more
europepmc   +1 more source

PARP1 and PARP2 are dispensable for DNA repair by microhomology-mediated end-joining at double-ended DSBs. [PDF]

Nucleic Acids Res
Ortega R, Taylor ER, Whitehead SM, Danhorn T, Bitler BG, Arnoult N.   +5 more
europepmc   +1 more source

Synthetic lethality from the combination of a histone methyltransferase SUV39H2 inhibitor and a poly (ADP-ribose) polymerase inhibitor for uterine leiomyosarcoma. [PDF]

BMC Cancer
Toyohara Y, Sone K, Kumegawa K, Yamamoto Y, Hachijo R, Kukita A, Taguchi A, Ikemura M, Miyamoto Y, Tanikawa M, Iriyama T, Mori M, Hamamoto R, Ushiku T, Oda K, Hirota Y, Maruyama R, Osuga Y.   +17 more
europepmc   +1 more source

Microenvironmental acidosis drives PARP- and ATM inhibitor resistance in p53 deficient pancreatic cancer. [PDF]

iScience
Ialchina R, Simonsen TR, Andersen HB, Stigliani A, Dai Y, Yao J, Larsen T, Czaplinska D, Pardo LA, Sandelin A, Pedersen SF.   +10 more
europepmc   +1 more source

SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression. [PDF]

Cancer Res Commun
Corr BR, Woodruff ER, Yamamoto TM, Jordan KR, Danhorn T, Bossard C, Nguyen LL, Chuong EB, Wick L, Young A, Kusumoto S, Orsulic S, Barroilhet L, Bitler BG.   +13 more
europepmc   +1 more source

Olaparib Response in a Patient With Platinum-Refractory Germ Cell Tumor Harboring a Somatic <i>BRIP1</i> Mutation. [PDF]

JCO Precis Oncol
Gismondi CBL, Agarwal R, Teixeira MFB, Chehrazi-Raffle A.   +3 more
europepmc   +1 more source

Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer. [PDF]

J Immunother Cancer
Li C, Madan RA, Lee MJ, Lee S, Sato N, Rastogi S, Shrestha R, Aragon-Ching JB, Goswami M, Donahue RN, Cordes LM, Baj A, Seo CCY, Terrigino NT, Bright JR, Hennigan ST, King IM, Trostel SY, Fenimore JM, Liu Y, Calzone KA, Schlom J, Gulley JL, Dahut WL, Figg WD, Sowalsky AG, Lee JM, Karzai F.   +27 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Olaparib

Reactions Weekly
  +18 more sources